Labcorp shares are trading higher after the company announced that the FDA approved its nABCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic, to determine patient eligibility for treatment with BEQVEZ.
Laboratory Corporation of America Holdings +2.98% Pre
Laboratory Corporation of America Holdings LH | 220.51 220.51 | +2.98% 0.00% Pre |
Labcorp shares are trading higher after the company announced that the FDA approved its nABCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic, to determine patient eligibility for treatment with BEQVEZ.